Uniphar Group is a trusted global partner to pharma, medtech and biotech companies, working to improve patient access to medicines around the world. Uniphar’s team of experts harness the capabilities, infrastructure and expertise of a diversified pharmaceutical service provider with more than 57 years’ building success stories with 200+ multinational clients. Our understanding of the shifting market dynamics allows us to deliver tailored specialist services and solutions for our clients’ changing needs. Uniphar Pharma comprises of Uniphar | Clinical & Development, Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial – together our combined capabilities make us your trusted partner to unlock access for your patients to innovative therapies and optimize value for brands globally. Partnering from clinical development to commercialisation, Uniphar’s global presence and in-depth market expertise remove barriers to launch and enhance pathways to life changing therapies. Connecting the dots from molecule to market.
The Medicine Accelerator
The Medicine Accelerator (TMA) is a privately owned, science driven, diverse modality CDMO partner that specializes in bioprocess engineering, process development and GMP manufacturing to create scale-up strategies for effective and fully portable tech transfer and manufacturing control for CGT, vaccines, peptides, ATMPs, small and large molecules. TMA’s proprietary, first in class, iAchieve® cloud-based knowledge management platform tracks and curates data in real-time and provides visibility to every CMC decision made during a molecule’s journey. APC is a team of 300 strong with a 14-year track record of large pharma and biotech partnerships demonstrating significant process, recovery, timeline, and COGs improvements for mammalian, human, and microbial systems. Construction is ongoing to double our footprint and staff in 2026.
SiriusXT Ltd
SiriusXT has developed the only commercially-available laboratory instrument that is capable of non-destructively imaging the whole internal structure of intact cells or tissue slabs, with high natural contrast (label-free) and with nanometer-resolution. The microscope, called a Soft X-ray Microscope, uses an imaging modality that has been in use for over 30 years but which has only been available at six global, football stadium-sized, research facilities, called synchrotrons. SiriusXT has effectively miniaturized the synchrotron into a chamber measuring less than 3 feet in diameter, enabling the development of a table-top microscope. This means that the benefits of soft X-ray microscopy are now accessible 24/7, without having to wait for up to 12 months to get access to the synchrotron microscopes. Despite the very restricted access to the synchrotron-based microscopes many hundreds of peer-reviewed papers have been published by scientists working in disease research and therapeutic discovery where the images produced by the microscopes have helped in making significant advances in scientific state of the art. In biological research, Soft X-ray Microscopy can be used as a stand-alone cell and tissue structural imaging technique, where it can image sample thicknesses that are close to 50 times greater than can be imaged with electron microscopy. It can also be used in correlative imaging workflows, along with light and electron microscopy, to greatly increase (by a factor of over 20 times) the sample imaging throughput. Thirdly, it has been demonstrated that Soft X-ray Microscopy provides an effective means for tracking and validating the delivery of nanoparticle, carrying a cargo of therapeutics, vaccines or adjuvants, to targeted end points in cells. SiriusXT has commissioned its first commercial product, the SXT-100, in 2024 at a research university in Europe. It is now focused on introducing the SXT-100 to target customers in the US.
National Institute for Bioprocessing Research and Training
NIBRT’s mission is to help the growth and development of the biopharma manufacturing industry by providing cutting edge training and research solutions. Based in Dublin, Ireland with Global Partners in Houston, Maryland, Canada, Senegal and South Korea.
MIAS Pharma Ltd
MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU regulations. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provide oversight of: – European Qualified Person (QP) services – Regulatory compliance of manufacturing activities – Regulatory compliance of Repackaging / Relabeling services – Regulatory compliance of Shipment and Transportation activities – Compliance with responsibilities as a Market Authorisation Holder (MAH) MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients’ requirements. | MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Primary customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU / UK regulations. In recent times MIAS also supports CMOs, CROs, Packaging companies and Testing companies QP solutions to take the burden off internal resources. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provides: 1. European & UK Qualified Person (QP & QA) services 2. QP Audit programs 3. QMS Design: WDA & MIA 4. Turnkey EU Launch solutions: Packaging, Labelling, Distribution & Testing (Via Alliances) 6. Support for IMPD and Market Authorisation (MA) submissions MIAS operates in a hub and spoke model with a core group of MIAS employees being able to rely on a group of international associates to flex up/down capacity depending on clients requirements. | MIAS Pharma Supports Companies to carry out both Clinical Studies and Commercial Product launches in Europe and the UK. We hold licences known as MIA’s which allow us to import and QP release your products. As part of our service offering we can support you with: – EU / UK set-up – We can support your IMPD / MA submissions – Via our partner companies we can support Market Access, commercialisation and Distribution – QP Release – Product testing and retains – Audit Programs – WDA and RP Services
Our mission is to organize the world’s information and make it universally accessible and useful. | Google Public Sector helps federal, state, and local governments empower their workforce and improve the lives of their constituents with our secure, interoperable, intelligent platform. Whether you’re looking to build new applications in the cloud or transform current infrastructure, we can help modernize service delivery to focus on your mission. | Google’s expertise and technology are driving measurable improvements in global health outcomes through innovative solutions tailored to both patients and healthcare organizations. Google empowers healthcare businesses and delivers tangible value by providing patients with high-quality tools and information, healthcare organizations with transformative care and operational solutions, and public health agencies with data-driven insights. Fueled by AI research and a commitment to health equity, we strive to revolutionize the patient experience, optimize operations, and democratize access to healthcare, building a healthier future for everyone. | Discover powerful customer and employee experiences with Google Discover powerful experiences with Google. Deliver seamless solutions for kiosks and digital signage through ChromeOS, experience a new communication technology that lets you be there from anywhere with Google Beam, or make every meeting matter with Google Meet. Secure-by-design infrastructure and AI-powered technology delivers a fast, frictionless and impactful experience. Visit the Google stand 2S500.
AVA Solutions
Fleet management and digitization in quarries streamline data collection, enhancing efficiency and visibility. Quarry groups, individual sites and contractors! Single view for maximum efficiency and simplicity.